Shares of Mesoblast Limited (NASDAQ:MESO - Get Free Report) gapped down before the market opened on Thursday . The stock had previously closed at $10.95, but opened at $10.68. Mesoblast shares last traded at $10.70, with a volume of 14,462 shares traded.
Analyst Ratings Changes
Several research analysts have recently issued reports on MESO shares. Piper Sandler reiterated an "overweight" rating and issued a $24.00 price objective (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
View Our Latest Analysis on MESO
Mesoblast Price Performance
The firm has a 50 day moving average price of $11.26 and a two-hundred day moving average price of $13.99. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.
Hedge Funds Weigh In On Mesoblast
A number of institutional investors have recently bought and sold shares of MESO. Strategic Financial Concepts LLC purchased a new position in Mesoblast during the 4th quarter worth approximately $2,744,000. Bank of America Corp DE boosted its position in Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock worth $5,756,000 after acquiring an additional 272,595 shares during the period. Quadrant Capital Group LLC boosted its position in Mesoblast by 41.1% during the 4th quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock worth $129,000 after acquiring an additional 1,891 shares during the period. LPL Financial LLC grew its stake in Mesoblast by 7.7% during the 4th quarter. LPL Financial LLC now owns 38,882 shares of the company's stock valued at $770,000 after acquiring an additional 2,795 shares in the last quarter. Finally, Barclays PLC acquired a new position in shares of Mesoblast in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Recommended Stories
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
